Boston Scientific launches Promus Element coronary stent system
2 March 2012
Boston Scientific Corporation (NYSE: BSX) has launched its
Promus Element Everolimus-Eluting platinum chromium coronary stent
system in Japan, following regulatory approval.
The stent incorporates a platinum chromium (PtCr) alloy with an
innovative stent design and an advanced catheter delivery system
designed to provide physicians improved drug-eluting stent
performance in treating patients with coronary artery disease.
"We are very pleased to launch the PROMUS Element Stent System to
Japanese physicians and their patients," said Yusuke Naiki,
President of Boston Scientific Japan. "This everolimus-based stent
system complements our broad coronary intervention portfolio and
reinforces our global leadership in the drug-eluting stent market."
The Promus Element Stent uses a proprietary PtCr alloy designed
specifically for coronary stenting, which enables enhanced
visibility, less recoil, excellent conformability and higher radial
strength. It employs an advanced low-profile delivery system to
enable precise stent placement across challenging lesions.
The everolimus drug and fluorinated copolymer used on the
stent have been studied in multiple randomized clinical trials and
registries. The stent expands Boston Scientific's PtCr drug-eluting
stent portfolio in Japan, which also includes the TAXUS Element
Paclitaxel-Eluting Platinum Chromium Coronary Stent System.
"This approval marks two important milestones for Boston
Scientific," said Hank Kucheman, Chief Executive Officer of Boston
Scientific. "First, the PROMUS Element Stent platform is now
approved in every major market worldwide. Second, we have begun the
last phase of our transition to higher margins on our everolimus
stent offering as we shift to the internally manufactured Promus
Element Stent. Boston Scientific remains the only company to offer
physicians a choice of two proven drug and polymer combinations on
an innovative coronary stent platform."
Source: Boston Scientific